Article Information
History
- December 14, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Chemtai Mungo1,2,*,
- Elizabeth Bukusi3,
- Grace E Kirkland4,
- Cirillus Ogollah3,
- Gershon Rota3,
- Jackton Omoto5 and
- Lisa Rahangdale1,2
- 1Department of Obstetrics and Gynecology, University of North Carolina Chapel Hill, 321 S Columbia St, Chapel Hill, North Carolina, 27599, USA
- 2Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, 450 West Dr, Chapel Hill, North Carolina, 27599, USA
- 3Kenya Medical Research Institute, Busia Rd, Kisumu, Kenya
- 4School of Medicine, University of North Carolina Chapel Hill, 321 S Columbia St, Chapel Hill, North Carolina, 27599, USA
- 5Department of Obstetrics and Gynecology, Maseno University School of Medicine, P.O, Kisumu, Kenya
- ↵*Corresponding author:
Chemtai Mungo, MD, MPH, Chemtai_mungo{at}med.unc.edu
Posted December 14, 2023.
Feasibility of adjuvant self-administered intravaginal 5-fluorouracil cream following primary treatment of cervical intraepithelial neoplasia grade 2 or 3 among women living with HIV in Kenya: study protocol for a pilot trial
